Opdivo/Yervoy (Regimen) BMS Oncology Co-Pay Assistance Program: Eligible commercially insured patients may pay no more than $25 per infusion with savings of up to $25,000 per calendar year; for additional information contact the program at 800-861-0048. Applies to: Opdivo Yervoy Regimen Number of uses: per prescription per calendar year
What are the adverse reactions of Yervoy?from opdivohcp.com
Severe or fatal cases have been reported for some of these adverse reactions: cardiac/vascular: myocarditis, pericarditis, vasculitis; nervous system : meningitis, encep halitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy; ocular: uveitis, iritis, and other ocular inflammatory toxicities can occur; gastrointestinal: pancreatitis to include increases in serum amylase and lipase levels, gastritis, duodenitis; musculoskeletal and connective tissue: myositis/polymyositis, rhabdomyolysis, and associated sequelae including renal failure, arthritis, polymyalgia rheumatica; endocrine: hypoparathyroidism; other (hematologic/immune): hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis (HLH), systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection.
What is OPDIVO used for?from opdivohcp.com
OPDIVO is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT). OPDIVO, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment ...
What is odivo in cancer?from opdivohcp.com
OPDIVO ® (nivolumab), in combination with YERVOY ® (ipilimumab), is indicated for the treatment of adults and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
What is opdivo nivolumab?from opdivohcp.com
OPDIVO ® (nivolumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
What is the name of the drug that is used to treat pleural mesothelioma?from opdivohcp.com
OPDIVO ® (nivolumab), in combination with YERVOY ® (ipilimumab), is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM).
What is nivolumab used for?from opdivohcp.com
OPDIVO ® (nivolumab) is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.
Can opdivo cause fetal harm?from opdivohcp.com
Based on its mechanism of action and findings from animal studies, OPDIVO and YERVOY can cause fetal harm when administered to a pregnant woman. The effects of YERVOY are likely to be greater during the second and third trimesters of pregnancy. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with OPDIVO and YERVOY and for at least 5 months after the last dose.
Why are Opdivo and Yervoy taken together?
But they’re also commonly given together. In fact, Opdivo and Yervoy are FDA-approved to be given together to treat the following cancers :
What are common side effects of Opdivo and Yervoy?
They can cause the immune system to attack healthy cells, causing immune-related side effects like skin rashes or severe diarrhea. Side effects can occur during or after treatment, and may worsen over time. And when Opdivo and Yervoy are given in combination together, the risk of side effects may be higher .
Does Bristol Myers Squibb provide free medical care?
The Bristol Myers Squibb Patient Assistance Foundation (BMSPAF), a charitable organization, may also provide medicine, free of charge, to eligible, uninsured patients who have an established financial hardship. For more information and eligibility criteria, visit bmspaf.org.
Does Bristol Myers Squibb guarantee reimbursement?
Bristol Myers Squibb cannot guarantee that a patient will receive assistance. The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.
Does Bristol Myers Squibb guarantee reimbursement?
Bristol Myers Squibb cannot guarantee that a patient will receive assistance. The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.
Does Bristol Myers Squibb provide free medical care?
The Bristol Myers Squibb Patient Assistance Foundation (BMSPAF), a charitable organization, may also provide medicine, free of charge, to eligible, uninsured patients who have an established financial hardship. For more information and eligibility criteria, visit bmspaf.org.
What is OPDIVO in combination with?
OPDIVO, in combination with YERVOY ® (ipilimumab), is indicated for the treatment of patients with unresectable or metastatic melanoma.
What is OPDIVO used for?
OPDIVO is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT). OPDIVO, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment ...
What is odivo in cancer?
OPDIVO ® (nivolumab), in combination with YERVOY ® (ipilimumab), is indicated for the treatment of adults and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
What is opdivo nivolumab?
OPDIVO ® (nivolumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
What is the name of the drug that is used to treat pleural mesothelioma?
OPDIVO ® (nivolumab), in combination with YERVOY ® (ipilimumab), is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM).
What is nivolumab used for?
OPDIVO ® (nivolumab) is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.
Does opdivo cause liver toxicity?
OPDIVO in combination with cabozantinib can cause hepatic toxicity with higher frequencies of Grade 3 and 4 ALT and AST elevations compared to OPDIVO alone. Consider more frequent monitoring of liver enzymes as compared to when the drugs are administered as single agents. In patients receiving OPDIVO and cabozantinib, Grades 3 and 4 increased ALT or AST were seen in 11% of patients.
What Are Nivolumab (Opdivo) + Ipilimumab (Yervoy)?
Nivolumab is an anti-PD-1 drug, which is an antibody that promotes the tumor-killing effects of T-cells (white blood cells that help your body fight disease). Ipilimumab is an anti-CTLA-4 drug, which is an antibody that helps strengthen the immune system by promoting the function and growth of T-cells.
How Are Nivolumab and Ipilimumab Given?
Patients receive both medications intravenously (into a blood vein). During the first phase of this therapy, patients receive both medications on the same day, as follows:
What Are the Goals of Nivolumab and Ipilimumab?
The combination of nivolumab and ipilimumab works as a systemic treatment to promote an immune response , with the goals of:
What is ipilimumab anti-CTLA-4?
Ipilimumab is an anti-CTLA-4 drug, which is an antibody that helps strengthen the immune system by promoting the function and growth of T-cells. Both medications: Are a type of immunotherapy known as checkpoint inhibitors, a type of immunotherapy that energizes your body's own immune system to attack the cancer cells.
How long does it take to take nivolumab?
The recommended dose and schedule of nivolumab is 1 mg/kg administered intravenously over 60 minutes.
Is Opdivo a separate drug?
Learn more about nivolumab ( Opdivo) and ipilimumab (Yervoy) as separate drugs.
Does ipilimumab block PD-1?
By blocking CTLA-4, ipilimumab activates your immune system against melanoma by allowing T cells to multiply and increase your body's immune response. Nivolumab blocks a different checkpoint molecule called PD-1, which helps protect tumor cells from being attacked by your immune system. Nivolumab removes the PD-1 "shield" to allow your immune ...
How much does Yervoy cost?
The cost for Yervoy intravenous solution (5 mg/mL) is around $8,078 for a supply of 10 milliliters, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans.
What is Yervoy used for?
Yervoy (ipilimumab) is a member of the anti-CTLA-4 monoclonal antibodies drug class and is commonly used for Colorectal Cancer, Malignant Pleural Mesothelioma, Melanoma, and others .
How much does a free drug card save?
The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.
How much does Opdivo cost?
The cost for Opdivo intravenous solution (10 mg/mL) is around $1,189 for a supply of 4 milliliters, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans.
What is Opdivo used for?
Opdivo (nivolumab) is a member of the anti-PD-1 monoclonal antibodies drug class and is commonly used for Colorectal Cancer, Esophageal Carcinoma, Head and Neck Cancer, and others.
How much does a free drug card save?
The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.
